Barinthus Biotherapeutics (BRNS) Accumulated Expenses (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has 7 years of Accumulated Expenses data on file, last reported at $8.7 million in Q1 2026.

• Quarterly Accumulated Expenses rose 20.66% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (up 20.66% YoY) and the FY2025 annual result came in at $6.2 million, down 34.39% from the prior year.
• Accumulated Expenses improved to $8.7 million in Q1 2026, from $6.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.9 million in Q3 2023 to a low of $6.2 million in Q4 2025.
• A 5-year average of $8.4 million and a median of $8.1 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 6155.17% — and 2025, when it tumbled 34.39%.
• Tracing BRNS's Accumulated Expenses over 5 years: stood at $8.1 million in 2022, then climbed by 14.28% to $9.2 million in 2023, then increased by 3.4% to $9.5 million in 2024, then sank by 34.39% to $6.2 million in 2025, then surged by 38.98% to $8.7 million in 2026.
• The last three Accumulated Expenses figures came in at $8.7 million (Q1 2026), $6.2 million (Q4 2025), and $6.7 million (Q3 2025), per Business Quant data.